Here is more on the open label, post hoc data suggesting that sotatercept added to standard of care background therapies improves clinical outcomes in seriously ill cardiac patients. Merck itself put out this presser, this morning -- and a bit:
. . .[Merck & Co.] today announced new analyses from studies of sotatercept, Merck’s novel investigational activin signaling inhibitor biologic, for adults with pulmonary arterial hypertension (PAH) (WHO Group 1) at the European Respiratory Society (ERS) International Congress 2023.
A new exploratory post-hoc analysis of right heart catheterization and echocardiography data from patients in the Phase 3 STELLAR study showed treatment with sotatercept for 24 weeks on top of background therapy reduced right heart size and improved right-ventricular (RV) function and hemodynamic status. This analysis was featured in an oral presentation, with simultaneous publication in the European Respiratory Journal. An interim analysis of the Phase 3 SOTERIA open-label extension study was also presented, representing the longest safety and efficacy analysis of sotatercept to date. . . .
Do go read it all, as my eldest has landed in the Big Apple this morning, most recently from Reykjavík, Iceland (by way of London for most of the two months before September) -- headed into the Rockies by week's end, after a bridal party appearance. Smile. Getting pumped for it all. . . .
नमस्ते
No comments:
Post a Comment